Our first cohort consisted of a control line (healthy individual, the 40102 line), a PD patient with a duplication of the α- synuclein gene (denoted as 2X), and a PD patient with a triplication of the α-synuclein gene (denoted as 3X). The gene discussed is SNCA; the disease is Parkinson disease.